Clinical Trials Logo

Malaria, Falciparum clinical trials

View clinical trials related to Malaria, Falciparum.

Filter by:

NCT ID: NCT05676645 Recruiting - Malaria,Falciparum Clinical Trials

Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs

MILK Malaria
Start date: March 20, 2023
Phase:
Study type: Observational
Read more »
NCT ID: NCT05604521 Terminated - Malaria Clinical Trials

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Start date: December 6, 2022
Phase: Phase 1
Study type: Interventional

USSPZV7 is a randomized, phase 1, double-blind, placebo-controlled trial of Sanaria® PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity, and vaccine efficacy (VE) against heterologous controlled human malaria infection (CHMI) with the 7G8 clone of Plasmodium falciparum (Pf) conducted at 3 or 12 weeks after the third immunization. The trial is designed to determine if individuals living in a non-malaria endemic area such as the United States (US) are protected against heterologous CHMI conducted at these time points.

NCT ID: NCT05567016 Active, not recruiting - Malaria Clinical Trials

CHILD (Child Health and Infection With Low Density) Malaria

Start date: July 18, 2023
Phase: N/A
Study type: Interventional

This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania

NCT ID: NCT05550909 Completed - Malaria,Falciparum Clinical Trials

Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

NECTAR4
Start date: October 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine-amodiaquine (ALAQ) with and without a single dose of 0.25mg/kg primaquine (PQ). Outcome measures will include infectivity to mosquitoes at 2, 7 and 14 days after treatment, gametocyte density throughout follow-up, and safety measures including haemoglobin density and the frequency of adverse events.

NCT ID: NCT05507970 Completed - Malaria,Falciparum Clinical Trials

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Start date: July 29, 2022
Phase: Phase 1
Study type: Interventional
Read more »
NCT ID: NCT05468606 Recruiting - Malaria,Falciparum Clinical Trials

Coadministration of GA2 Sporozoites With Adjuvants

CoGA
Start date: February 3, 2023
Phase: Early Phase 1
Study type: Interventional

This study will assess the coadministration of genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites with adjuvants (BCG and YF-17D vaccination and imiquimod cream). Primary outcomes will be safety, tolerability and protective efficacy against CHMI.

NCT ID: NCT05400746 Recruiting - Malaria Clinical Trials

A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

Start date: November 2, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK

NCT ID: NCT05385471 Recruiting - Malaria, Falciparum Clinical Trials

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults

Start date: January 13, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M

NCT ID: NCT05357560 Recruiting - Clinical trials for Malaria, Plasmodium Falciparum

A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

Start date: July 10, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ib multi-stage Plasmodium falciparum malaria vaccine study to assess the safety and immunogenicity of the blood-stage vaccine candidate RH5.2 virus-like particle (VLP) in Matrix-MTM and the pre-erythrocytic stage vaccine candidate R21 in Matrix-MTM, both alone and in combination, in adults and infants in the Gambia

NCT ID: NCT05306067 Recruiting - Malaria Clinical Trials

Plasmodium Falciparum Genomic Intelligence in Mozambique

GenMoz
Start date: October 12, 2021
Phase:
Study type: Observational
Read more »